Cited 17 times in
Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김건민 | - |
dc.contributor.author | 최혜진 | - |
dc.contributor.author | 한광협 | - |
dc.contributor.author | 한정우 | - |
dc.date.accessioned | 2016-02-04T11:55:34Z | - |
dc.date.available | 2016-02-04T11:55:34Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/141504 | - |
dc.description.abstract | BACKGROUND AND AIM: Sorafenib is now considered as a standard treatment for advanced hepatocellular carcinoma (HCC). We evaluated the effect of hepatitis B virus (HBV) DNA titers on prognosis in HCC patients treated with sorafenib. METHODS: From 2008 to 2012, 78 HBV-related HCC patients who received sorafenib treatment at Severance Hospital were included in our analysis. The effect of pretreatment HBV-DNA levels on clinical outcomes for use in predicting prognosis after treatment with sorafenib was examined by univariate and multivariate analysis. RESULTS: Median overall survival and median progression-free survival were 5.2 months (95% confidence interval: 4.0-6.4) and 3.5 months (95% confidence interval: 2.3-4.7), respectively. Multivariate analysis revealed high levels of HBV-DNA (> 2000 IU/mL) to be an independent risk factor for worse overall survival (P=0.005; hazard ratio, 2.85) and disease progression among patients who did not receive concomitant prophylactic antiviral therapy during sorafenib treatment (P=0.008; hazard ratio, 87.4). Moreover, viral reactivation occurred more frequently in patients who did not receive concomitant prophylactic antiviral therapy than in those who did (4/38 vs 0/40; P=0.025). CONCLUSION: Higher HBV-DNA levels prior to sorafenib treatment were associated with poorer prognosis and increased viral reactivation thereafter. These results suggest the potential usefulness of prophylactic antiviral therapy when treating HBV-related HCC patients with sorafenib. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1024~1031 | - |
dc.relation.isPartOf | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Antiviral Agents/administration & dosage* | - |
dc.subject.MESH | Biomarkers/blood | - |
dc.subject.MESH | Carcinoma, Hepatocellular/drug therapy* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/mortality | - |
dc.subject.MESH | Carcinoma, Hepatocellular/virology | - |
dc.subject.MESH | DNA, Viral/blood | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Forecasting | - |
dc.subject.MESH | Hepatitis B virus*/genetics | - |
dc.subject.MESH | Hepatitis B virus*/physiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Neoplasms/drug therapy* | - |
dc.subject.MESH | Liver Neoplasms/mortality | - |
dc.subject.MESH | Liver Neoplasms/virology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Niacinamide/administration & dosage | - |
dc.subject.MESH | Niacinamide/analogs & derivatives* | - |
dc.subject.MESH | Niacinamide/therapeutic use | - |
dc.subject.MESH | Phenylurea Compounds/administration & dosage | - |
dc.subject.MESH | Phenylurea Compounds/therapeutic use* | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Viral Load* | - |
dc.subject.MESH | Virus Activation | - |
dc.title | Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Seungtaek Lim | - |
dc.contributor.googleauthor | Jungwoo Han | - |
dc.contributor.googleauthor | Gun Min Kim | - |
dc.contributor.googleauthor | Kwang Hyub Han | - |
dc.contributor.googleauthor | Hye Jin Choi | - |
dc.identifier.doi | 10.1111/jgh.12898 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00287 | - |
dc.contributor.localId | A04219 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A04325 | - |
dc.relation.journalcode | J01417 | - |
dc.identifier.eissn | 1440-1746 | - |
dc.identifier.pmid | 25611175 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/jgh.12898/abstract | - |
dc.subject.keyword | hepatocellular carcinoma | - |
dc.subject.keyword | sorafenib | - |
dc.subject.keyword | viral load | - |
dc.contributor.alternativeName | Kim, Gun Min | - |
dc.contributor.alternativeName | Choi, Hye Jin | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.alternativeName | Han, Jung Woo | - |
dc.contributor.affiliatedAuthor | Kim, Gun Min | - |
dc.contributor.affiliatedAuthor | Choi, Hye Jin | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Han, Jung Woo | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 30 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1024 | - |
dc.citation.endPage | 1031 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.30(6) : 1024-1031, 2015 | - |
dc.identifier.rimsid | 30688 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.